My watch list
my.bionity.com  
Login  

Abarceo Pharma has identified a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce their own insulin again, naturally.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE